About the Company
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
111
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EVLO News
Evelo Biosciences, Inc. (EVLO) stock forecast and price target
Find the latest Evelo Biosciences, Inc. EVLO analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines ...
Why Root Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Evelo Biosciences, Inc. (NASDAQ: EVLO) fell 8.4% to $0.1465 in pre-market trading after dropping 9% on Wednesday. Catalyst Biosciences, Inc. (NASDAQ: CBIO) shares dropped 8.3% to $0.32 in pre ...
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.01%
Onfolio Holdings Inc (NASDAQ:ONFO) which lost 34.58% to settle at 0.54 and Evelo Biosciences Inc (NASDAQ:EVLO) which was down 32.65% to 0.49 at the close. Rising stocks outnumbered declining ones ...
North American Morning Briefing: Investors -2-
Enliven Therapeutics Inc (ELVN) is expected to report $-0.54 for 4Q. Evelo Biosciences Inc (EVLO) is expected to report for 4Q. Exscientia PLC - ADR (EXAI) is expected to report $-0.37 for 4Q.
Evelo Biosciences, Inc. (EVLO)
Horizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Greetings, and welcome to Horizon Technology Finance Corporation Third Quarter 2023 ...
Flagship V VentureLabs Rx Fund, L.P.'s Net Worth
Inc., Codiak BioSciences, Inc., Evelo Biosciences, Inc., and Rubius Therapeutics, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro!
Ardagh Metal Packaging Stock (NYSE:AMBP), Quotes and News Summary
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences ...
YTEN Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds.
Kaleido Biosciences Inc KLDO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Loading the latest forecasts...